All In Biotech

Drug Trial Radar · NCT04643249

Drug-drug Interaction Study of KL1333 in Healthy Subjects

A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Oct 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Nov 10, 2020

Primary completion

Dec 17, 2020

Study completion Dec 17, 2020

Sponsor

Lead sponsor
Abliva ABIndustry
Sponsor type
Industry
First posted
Nov 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects

Conditions

  • Mitochondrial Disease

Interventions

  • KL1333Drug

    Tablet

  • FlurbiprofenDrug

    Tablet

  • DextromethorphanDrug

    Syrap

  • BupropionDrug

    Tablet

  • Midazolam injectionDrug

    solution for injection

  • OmeprazoleDrug

    Capsule

  • CaffeineDrug

    Tablet or capsule

  • RepaglinideDrug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determination of the effect of KL1333 on the PK of repaglinide, caffeine, omeprazole, midazolam, bupropion, dextromethorphan, and flurbiprofen in healthy subjects.Time frame: day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Volunteer recruitment center Covance Leeds Covance Leeds

    Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.